

William A Weiss

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8249192/william-a-weiss-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

17,320
citations

59
h-index

131
g-index

146
ext. papers

19,654
ext. citations

13.2
avg, IF

6.02
L-index

#	Paper	IF	Citations
140	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544	16.2	2783
139	A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. <i>Cell</i> , 2006 , 125, 733-47	56.2	963
138	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. <i>Science</i> , 2014 , 343, 189-193	33.3	912
137	Principles and current strategies for targeting autophagy for cancer treatment. <i>Clinical Cancer Research</i> , 2011 , 17, 654-66	12.9	687
136	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012 , 488, 49-56	50.4	596
135	Targeted expression of MYCN causes neuroblastoma in transgenic mice. <i>EMBO Journal</i> , 1997 , 16, 2985-95	9.5	573
134	A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. <i>Cancer Cell</i> , 2006 , 9, 341-9	24.3	532
133	Targeting MYCN in neuroblastoma by BET bromodomain inhibition. <i>Cancer Discovery</i> , 2013 , 3, 308-23	24.4	460
132	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014 , 506, 445-50	50.4	434
131	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. <i>Cancer Cell</i> , 2011 , 20, 143-57	24.3	395
130	Neuroblastoma and MYCN. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2013 , 3, a014415	5.4	335
129	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012 , 482, 529-33	50.4	322
128	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2927-35	2.2	290
127	BET bromodomain inhibition of MYC-amplified medulloblastoma. <i>Clinical Cancer Research</i> , 2014 , 20, 912-25	12.9	227
126	Akt and autophagy cooperate to promote survival of drug-resistant glioma. <i>Science Signaling</i> , 2010 , 3, ra81	8.8	225
125	Recognizing and exploiting differences between RNAi and small-molecule inhibitors. <i>Nature Chemical Biology</i> , 2007 , 3, 739-44	11.7	211
124	Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. <i>Oncogene</i> , 2018 , 37, 1561-1575	9.2	210

123	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016 , 529, 351-7	50.4	206
122	Cytogenetic prognostication within medulloblastoma subgroups. <i>Journal of Clinical Oncology</i> , 2014 , 32, 886-96	2.2	199
121	Alternative splicing in cancer: implications for biology and therapy. <i>Oncogene</i> , 2015 , 34, 1-14	9.2	194
120	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 484-495	21.7	187
119	A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. <i>Cancer Research</i> , 2007 , 67, 7960-5	10.1	185
118	Non-stem cell origin for oligodendroglioma. <i>Cancer Cell</i> , 2010 , 18, 669-82	24.3	183
117	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. <i>Cancer Cell</i> , 2013 , 24, 438-49	24.3	181
116	Drugging MYCN through an allosteric transition in Aurora kinase A. <i>Cancer Cell</i> , 2014 , 26, 414-427	24.3	179
115	Asymmetry-defective oligodendrocyte progenitors are glioma precursors. <i>Cancer Cell</i> , 2011 , 20, 328-40	24.3	168
114	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. <i>Nature Chemical Biology</i> , 2007 , 3, 229-38	11.7	168
113	Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. <i>Cancer Research</i> , 2006 , 66, 8139-46	10.1	164
112	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011 , 122, 231-40	14.3	159
111	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. <i>Nature Medicine</i> , 2010 , 16, 1134-40	50.5	156
110	The prenatal origins of cancer. <i>Nature Reviews Cancer</i> , 2014 , 14, 277-89	31.3	153
109	Myc proteins as therapeutic targets. <i>Oncogene</i> , 2010 , 29, 1249-59	9.2	151
108	Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. <i>Nature Genetics</i> , 2005 , 37, 645-51	36.3	143
107	Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. <i>Cancer Cell</i> , 2012 , 21, 601-613	24.3	141
106	EGFR signals to mTOR through PKC and independently of Akt in glioma. <i>Science Signaling</i> , 2009 , 2, ra4	8.8	140

105	Pleiotropic role for MYCN in medulloblastoma. <i>Genes and Development</i> , 2010 , 24, 1059-72	12.6	128
104	Targeted therapy for BRAFV600E malignant astrocytoma. <i>Clinical Cancer Research</i> , 2011 , 17, 7595-604	12.9	128
103	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013 , 125, 373-84	14.3	126
102	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017 , 19, 153-161	1	125
101	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. <i>Cancer Cell</i> , 2015 , 27, 72-84	24.3	122
100	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. <i>Neuro-Oncology</i> , 2011 , 13, 384-92	1	118
99	Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 12664-9	11.5	118
98	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013 , 126, 917-29	14.3	115
97	Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity. <i>EMBO Reports</i> , 2008 , 9, 923-9	6.5	95
96	PI3K signaling in glioma--animal models and therapeutic challenges. <i>Brain Pathology</i> , 2009 , 19, 112-20	6	93
95	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. <i>Cancer Cell</i> , 2017 , 31, 424-435	4.3	90
94	Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 1394-403	9.7	86
93	Childhood tumors of the nervous system as disorders of normal development. <i>Current Opinion in Pediatrics</i> , 2006 , 18, 634-8	3.2	77
92	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018 , 20, 160-173	1	76
91	Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. <i>Oncogene</i> , 2009 , 28, 3121-31	9.2	74
90	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , 2014 , 134, 2437-47	7.5	73
89	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. <i>Journal of Clinical Investigation</i> , 2018 , 128, 446-462	15.9	72
88	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. <i>Neuro-Oncology</i> , 2012 , 14, 1146-52	1	69

87	Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. <i>Cancer Research</i> , 2009 , 69, 8429-37	10.1	66
86	Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. <i>Science Translational Medicine</i> , 2012 , 4, 115ra3	17.5	66
85	Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 8710-5	11.5	64
84	Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. <i>Oncogene</i> , 2002 , 21, 7453-63	9.2	59
83	Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. <i>Cancer Research</i> , 2005 , 65, 3617-23	10.1	59
82	STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. <i>Cancer Research</i> , 2015 , 75, 4302-11	10.1	58
81	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012 , 123, 515-27	14.3	57
80	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. <i>Nature Neuroscience</i> , 2015 , 18, 1236-46	25.5	56
79	Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. <i>Cancer Research</i> , 2007 , 67, 9435-42	10.1	55
78	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. <i>Cancer Letters</i> , 2011 , 306, 223-9	9.9	54
77	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. <i>Genes and Development</i> , 2012 , 26, 1780-96	12.6	54
76	Characterization of structurally distinct, isoform-selective phosphoinositide 3Kinase inhibitors in combination with radiation in the treatment of glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 841-50	6.1	54
75	Radiation dose estimation using preclinical imaging with ¹²⁴ I-metaiodobenzylguanidine (MIBG) PET. <i>Medical Physics</i> , 2010 , 37, 4861-7	4.4	52
74	Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. <i>Neoplasia</i> , 2008 , 10, 1268-74	6.4	52
73	Neural stem cell biology may be well suited for improving brain tumor therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 189-204	2.2	51
72	Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. <i>Clinical Cancer Research</i> , 2011 , 17, 2339-49	12.9	50
71	Autophagy and Akt promote survival in glioma. <i>Autophagy</i> , 2011 , 7, 536-8	10.2	45
70	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. <i>Blood</i> , 2019 , 133, 1119-1129	2.2	45

69	Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. <i>Cancer Research</i> , 2013 , 73, 4086-97	10.1	44
68	Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. <i>Cancer Discovery</i> , 2012 , 2, 450-7	24.4	44
67	Cross-activating c-Met/ α integrin complex drives metastasis and invasive resistance in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E8685-E8694	11.5	42
66	Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. <i>Seminars in Cancer Biology</i> , 2011 , 21, 245-55	12.7	39
65	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. <i>Oncogene</i> , 2018 , 37, 2850-2862	9.2	38
64	Glioblastoma cellular cross-talk converges on NF- κ B to attenuate EGFR inhibitor sensitivity. <i>Genes and Development</i> , 2017 , 31, 1212-1227	12.6	38
63	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. <i>Oncogene</i> , 2005 , 24, 829-37	9.2	38
62	Dual HDAC and PI3K Inhibition Abrogates NF- κ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018 , 78, 4007-4021	10.1	36
61	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015 , 21, 3750-8	12.9	35
60	Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. <i>Cancer Research</i> , 2010 , 70, 4520-7	10.1	35
59	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. <i>Clinical Cancer Research</i> , 2016 , 22, 5312-5321	12.9	35
58	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. <i>Oncotarget</i> , 2016 , 7, 57525-57544	3.3	32
57	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019 , 25, 433-446.e7	18	31
56	IKK/NF- κ B signaling contributes to glioblastoma stem cell maintenance. <i>Oncotarget</i> , 2016 , 7, 69173-69183	3.3	31
55	Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 12722-7	11.5	30
54	Isoform specific inhibitors of PI3 kinase in glioma. <i>Cell Cycle</i> , 2006 , 5, 2301-5	4.7	28
53	Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. <i>Journal of Cellular Biochemistry</i> , 2007 , 102, 1529-41	4.7	27
52	Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. <i>Current Biology</i> , 2002 , 12, 1386-94	6.3	27

51	Glial progenitors as targets for transformation in glioma. <i>Advances in Cancer Research</i> , 2014 , 121, 1-65	5.9	26
50	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 385-93	4.8	25
49	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E1480-9	11.5	24
48	Combined BRAF and MEK blockade for BRAF-mutant gliomas. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 495-505	4.8	24
47	EGFR Cooperates with EGFRVIII to Recruit Macrophages in Glioblastoma. <i>Cancer Research</i> , 2018 , 78, 6785-6794	16.7	24
46	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012 , 123, 485-499	14.3	23
45	BMPs oppose Math1 in cerebellar development and in medulloblastoma. <i>Genes and Development</i> , 2008 , 22, 693-9	12.6	22
44	Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo. <i>Protein Science</i> , 2016 , 25, 308-15	6.3	22
43	Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 419-28	6.1	20
42	Blockade of glioma proliferation through allosteric inhibition of JAK2. <i>Science Signaling</i> , 2013 , 6, ra55	8.8	20
41	EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. <i>Oncotarget</i> , 2015 , 6, 21993-2005	9.9	19
40	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. <i>Child's Nervous System</i> , 2012 , 28, 521-32	1.7	18
39	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. <i>Child's Nervous System</i> , 2011 , 27, 1243-9	1.7	18
38	Inhibiting 4EBP1 in Glioblastoma. <i>Clinical Cancer Research</i> , 2018 , 24, 14-21	12.9	16
37	Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. <i>Frontiers in Oncology</i> , 2015 , 5, 111	5.3	16
36	Genetics of brain tumors. <i>Current Opinion in Pediatrics</i> , 2000 , 12, 543-8	3.2	16
35	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. <i>Oncotarget</i> , 2017 , 8, 583-595	3.3	16
34	What underlies the diversity of brain tumors?. <i>Cancer and Metastasis Reviews</i> , 2013 , 32, 5-24	9.6	15

33	Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. <i>Cell Reports</i> , 2014 , 9, 1034-46	10.6	14
32	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. <i>Epigenetics</i> , 2013 , 8, 1254-60	5.7	14
31	A CK1 α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. <i>Clinical Cancer Research</i> , 2019 , 25, 1379-1388	12.9	14
30	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF- β 2-SNAIL via PTEN inhibition. <i>Brain</i> , 2018 , 141, 1300-1319	11.2	13
29	Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. <i>Oncogene</i> , 2017 , 36, 6306-6314	9.2	13
28	The genetics of splicing in neuroblastoma. <i>Cancer Discovery</i> , 2015 , 5, 380-95	24.4	13
27	It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2013 , 19, 5811-3	12.9	13
26	Adenovirus-mediated hPase(ol-35) gene transfer as a therapeutic strategy for neuroblastoma. <i>Journal of Cellular Physiology</i> , 2009 , 219, 707-15	7	13
25	Brain tumors in S100 β -v-erbB transgenic rats. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006 , 65, 1111-7	3.1	13
24	Imaging-based chemical screening reveals activity-dependent neural differentiation of pluripotent stem cells. <i>ELife</i> , 2013 , 2, e00508	8.9	12
23	Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. <i>Molecular Cancer Research</i> , 2018 , 16, 777-790	6.6	10
22	An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. <i>Neuro-Oncology</i> , 2018 , 20, 1606-1615	1	10
21	A head holder for magnetic resonance imaging that allows the stereotaxic alignment of spontaneously occurring intracranial mouse tumors. <i>Journal of Neuroscience Methods</i> , 2002 , 116, 1-7	3	10
20	Cholesterol: An Achilles Heel for Glioblastoma?. <i>Cancer Cell</i> , 2016 , 30, 653-654	24.3	9
19	High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery. <i>Cancer Investigation</i> , 2012 , 30, 343-63	2.1	8
18	The side story of stem-like glioma cells. <i>Cell Stem Cell</i> , 2009 , 4, 191-2	18	8
17	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. <i>Cancer Research</i> , 2021 , 81, 1627-1632	10.1	7
16	Depatuzumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR Phosphorylation. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1328-1339	6.1	6

15	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1565-1576	6.1	6
14	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.. <i>Nature Medicine</i> , 2022 ,	50.5	6
13	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2457-2460	12.9	5
12	When deletions gain functions: commandeering epigenetic mechanisms. <i>Cancer Cell</i> , 2014 , 26, 160-1	24.3	5
11	Recapitulating human cancer in a mouse. <i>Nature Biotechnology</i> , 2013 , 31, 392-5	44.5	5
10	G34, another connection between MYCN and a pediatric tumor. <i>Cancer Discovery</i> , 2013 , 3, 484-6	24.4	5
9	Utility of Human-Derived Models for Glioblastoma. <i>Cancer Discovery</i> , 2020 , 10, 907-909	24.4	4
8	Starvation favors glioma stem cells. <i>Nature Neuroscience</i> , 2013 , 16, 1359-61	25.5	4
7	Chemical genetic approaches to the development of cancer therapeutics. <i>Current Opinion in Genetics and Development</i> , 2006 , 16, 85-91	4.9	3
6	Neuroblastoma Metastases: Leveraging the Avian Neural Crest. <i>Cancer Cell</i> , 2017 , 32, 395-397	24.3	2
5	A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition. <i>Molecular and Cellular Oncology</i> , 2015 , 2, e975641	1.2	2
4	Betacellulin drives therapy resistance in glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 457-469	1	2
3	Can mouse models for brain tumors inform treatment in pediatric patients?. <i>Seminars in Cancer Biology</i> , 2004 , 14, 71-7	12.7	1
2	A translational end-run for a rare, genetically enigmatic tumor. <i>Cancer Biology and Therapy</i> , 2009 , 8, 2396-7	1	1
1	Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype. <i>Neuro-Oncology</i> , 2020 , 22, 175-176	1	1